Mike Glover

Honored to present results from the phase II GemFLP trial conducted at The University of Texas MD Anderson Cancer Center in advanced urachal and non-urachal urinary tract adenocarcinoma. Rapid Oral Session — Hall D2 Monday, June 1 | 8:00 AM #ASCO26 @mjmoussa_ @DocMattCampbell

Ab#4520 @ASCO #ASCO26 by @PavlosMsaouel👉 bit.ly/4nHgVqx👉Remarkable clinical activity of EGFR blockade (panitumumab) in SMARCB1-deficient renal medullary mRCC #kidneycancer👉Median PFS 5.8 mo & median OS 9.5 mo👇@NikiZacharias @BradMcG04 @OncoAlert @urotoday @kidneycan

@DrSpratticus @UHhospitals @CWRUSOM @VanderbiltU Hopefully they still have the bagpiper to lead you to Severance Hall! Great memories and great school

Honored to represent @UHhospitals at the 2026 @CWRUSOM graduation. Was more sentimental than I thought thinking back to @VanderbiltU med school graduation and the journey these past 16 years. Congrats to all of the brilliant and amazing graduates! 🎓. Change the world and realize we know very few things for certain. Challenge the status quo and discover! The impossible is simply the untried. If an ex-MMA bodybuilder can make a small difference, you all are unstoppable. @DanSimonMD @TedTeknosMD @CleClinicMD @metrohealthCLE @cwru @LPonsky @angela_jia_ @lauren_henke @UH_RE_Institute @UHSurgOncology @UHCMC_ED

📺 Watch @DocMattCampbell and @mjmoussa_ of @UTMDAnderson share findings from their study exploring the use of immune checkpoint inhibitors in patients with deficient mismatch repair/microsatellite instability–high #UTUC: buff.ly/YXgJYJW

Cisplatin as well! Many lives saved from the serendipity (and persistence and hard work) of Barnett Rosenberg cancer.gov/research/progr…

Dr. Larry Einhorn is known for revolutionizing testicular cancer treatment. His research resulted in a groundbreaking treatment that moved the survival rate from 5% to 95%. This testicular cancer awareness month, and every month, we are grateful to have him as a member of our Board of Directors and pillar of the Conquer Cancer community. #testiculatcancerawareness #testicularcancerawarenessmonth #ResearchConquersCancer #ConquerCancer

An incredible achievement. We can do very hard things

@sumitshahMD Beautiful interview and synopsis, Sumit. Some nice words about southeast Texas’s top mom and pop shop, too 😊

Every oncologist should watch Ben Sasse’s interview with Ross Douthat. I was captivated by his courage, serenity, and his ability to articulate what so many of our patients feel and experience. Ben and I don’t share the same political or religious beliefs, which made it all the more compelling. A few things stood out: * His physicians struggled to deliver the “hard facts.” They led with advances in oncology before telling him he had cancer, wanting to stay positive. I’ve been there - it’s incredibly tough to balance truth with hope. We need to be frank with our patients, even when it’s difficult. I also imagine that the story didn’t play out exactly as Ben recollected, but perception is reality for our patients. * Ben asked for “Oncology 101”: chemo vs. radiation vs. surgery vs. targeted therapy. He kept saying “teach me” - he needed a map. I love that. Every patient deserves this navigation. Cancer is overwhelming without a clear direction. * He’s on a drug targeting a cancer gene long considered “undruggable.” We’re making real progress and occasionally witnessing “miracles” in clinic - responses grounded in cancer biology. This progress depends on funding and clinical trials. This is how we move the field forward. * The flip side is that these treatments carry real toxicity. Ben’s face makes this painfully clear. I am constantly amazed at what many patients are willing to endure and the resilience that they show. * Ben loves his hospice team. They gave him a practical framework for managing four variables: cancer pain, nausea, balancing diarrhea and constipation, and energy/fatigue. He noted that oncologists often steer conversations to their own agenda (scans, treatment, etc). I’ve been guilty of this too. We need to listen more. * Despite being given a prognosis of a few months, Ben keeps his great sense of humor. After watching this, I feel we could actually be friends. Political labels might once have gotten in the way - and that’s on me. Confronting death strips away differences and magnifies what we share. * Ben on the digital culture we live in: “These super-devices in our pockets, the largest tools any individual has ever had, allow our consciousness to leave the time and place where we actually live… the places where we break bread, the people we can physically touch and hug.” This is so true. * Ben doesn’t fear death, but he fears misprioritization. Dinner time is precious. There’s a limit to work trips. Live near family. Cancer forces laser focus on what matters most. When people who are dying share these pearls, all of us need to listen and consider it a gift. Highly recommended. Wishing you the best, @BenSasse. nytimes.com/2026/04/09/opi…

@montypal Very kind of you, Monty. Thanks for listening!

Terrific episode! Well done @glovedoc.

Had a great time on @Uromigos talking about novel biomarkers and therapies in GCT. Exciting data on use of MiRNA/ctDNA to stratify/monitor disease and targeting CLDN6 and others. During Testicular Cancer Awareness month to boot! creators.spotify.com/pod/profile/th…

Really grateful for the opportunity to summarise key findings from our presentation at ASCO GU’26 on the @VuMedi platform. Check out their website for the latest updates in biomedicine. @DocMattCampbell @OAlhalabiMD @CYJiangMD @glovedoc @andrewjohnsmd vumedi.com/video/asco-gu-…

Stomp Out Cancer in honor of Dan Hund and his battle against adrenal cancer is in its 6th year stompoutcancer4dan.com all funds support rare tumor research with a new trial. Fill out a bracket at ESPN group is Dan Hund Memorial password stompoutcancer.

PhaseII trial of cabozantinib in refractory germ-cell tumors. Nice to see activity and clinical benefit in very refractory/heavily pretreated population. Important to continue drug development in this disease! @JenniferKingMD @IUCancerCenter @TestesCancer @TestesCancer

@DrZachariahT two posters today focused on GCT. 1) Somatic transformation (ST) is common as initial presentation in mediastinal NSGCT and is uniformly sarcoma. AdenoCA is a late transformation event 2) ctDNA can be detected in marker negative patients including ST pts #GU26

At #GU26 a tremendous overview of optimal trial design by @PavlosMsaouel. Pavlos has repeatedly shown that even in very rare cancers, optimally designed studies can rapidly led to practice changing findings. A visionary in our field.

Great talk @DrBenTran #GU26 with a study of Mi-RNA371 in stage 1 testicular cancer. How to practically integrate this test and balance vs tissue informed approach remains to be seen

Very proud of @DrZachariahT, a fantastic postdoc, and his great work on timing of enfortumab vedotin plus pembrolizumab toxicity and impact on outcome led by @OAlhalabiMD at #GU26

@EricTopol Per protocol is confounded as well. PCP probably more likely to use this tool if they suspect the diagnosis for other reasons

An AI stethoscope for primary care doctors was assessed in a randomized, controlled trial of >1.5 million patients to detect heart failure, valve disease and AF. It didn't help make the diagnoses. Because it wasn't used enough by the doctors. It improved diagnoses when it was used. New @TheLancet, an important lesson for AI med trials thelancet.com/journals/lance…

@williamyshi @CellCellPress @Kevinjliu_ @mohamshah @max_diehn @AshAlizadeh @liaojoe1 @arkhaki @StanfordUrology Congrats, will! Great work

Finally pee(r)-reviewed in @CellCellPress! Shoutout @Kevinjliu_, @mohamshah. Gratitude to @max_diehn @AshAlizadeh @liaojoe1 and all lab members for their mentorship and support, @arkhaki Eila Skinner @StanfordUrology and all co-authors. Excited to see it out in press!

@aphysicist If the data from MRI was perfect (its not) and we had effective treatment options for every scenario (we don't) then i would agree. but thats not reality

i think the reason there are a million counterfactual anecdotes with said data is because we haven't had the ability to process it effectively for patients into treatment, plus the sheer amount of anxiety that exists in medicine is overwhelming for people. it's going to take a long time

most doctors early on in med school are brainwashed to think MRI machines need gatekeeping. they're expensive, limited, critical use only. imagine thinking that a machine that can scan your entire body and help you prevent terrible things shouldn't be standard practice.